OPGN OpGen: Enterprise Value-to-Revenue Multiple

OpGen, Inc. (OPGN) growth relies on the sales of Acuitas systems for antibiotic resistance analysis. The EV/Sales trajectory confirms this dependency, where represents the current metric value. Innovative rapid pathogen diagnostic methods create technological potential; however, a critical shortage of funds and litigation regarding the assets of subsidiary firms seriously limit business development under current conditions.
OPGN (OpGen): analytical breakdowns and indicator data

This ratio compares the total enterprise value to annual revenue, excluding the impact of debt to determine the actual market premium per unit of revenue. By analyzing the enterprise value-to-revenue trajectory, an investor assesses the extent to which the market currently prices in the potential of OpGen, Inc. (OPGN) diagnostic systems to combat resistant infections into the asset's current capitalization.